Register
Abaloparatide fails to get EMA approval for use in osteoporosis |
Journal Updates
eMediNexus Coverage from: 
Abaloparatide fails to get EMA approval for use in osteoporosis
eMediNexus,  01 April 2018
remove_red_eye 914 Views
#Obstetrics and Gynecology #Orthopedics #Rheumatology

0 Read Comments                

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP), has rejected the marketing application for abaloparatide subcutaneous injection for postmenopausal women with osteoporosis at increased risk for fracture. The drug has been approved by US FDA for the same indication.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!